Medtronic PLC vs Philip Morris International Inc. — how do they compare? Medtronic PLC trades at $87.9 (market cap $109.38B), while Philip Morris International Inc. trades at $200.48 (market cap $300.33B). The key difference: Philip Morris International Inc. is far larger — about 2.7× Medtronic PLC's market cap, and Medtronic PLC pays the higher dividend (3.37%). Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Philip Morris International Inc. for 85 Days on average.
| MDT | PM | |
|---|---|---|
Market Cap | $109.38B | $300.33B |
Volume | 55,890,185 | 3,935,700 |
Sector | Health | Consumer Staples |
52-Week High | $105.35 | $200.50 |
52-Week Low | $73.75 | $144.33 |
Typical Hold Time | 63 Days | 85 Days |
Enterprise Value | $128.71B | $343.44B |
Dividend Yield | 3.37% | 3.32% |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $87.75, up 0.76% on the day, with strong analyst support (60.78% buy ratings) and a $97.80 consensus price target suggesting 11.4% upside. The stock shows consistent earnings beats in recent quarters with Q3 2026 results pending, while technical indicators signal bearish momentum despite oversold RSI readings. Recent positive developments include FDA clearances for new medical technologies and a 49-year dividend growth streak with a current 3.2% yield.
MDT presents a compelling value opportunity with reasonable valuation multiples (P/E 21.06, P/S 2.93) and improving fundamentals, though technical weakness and competitive pressures warrant caution. The company's revenue growth acceleration to $33.54B in 2025 and strong cash flow generation support the dividend sustainability, while debt levels have increased to 31.11% of assets, representing a key monitoring point for investors.
Philip Morris International (PM) trades at $200.5, up 5.3% over 24 hours, with a bullish technical signal and strong earnings beats in Q1 and Q2 2026. The company shows robust fundamentals with 2025 revenue of $40.65B and net income of $11.35B, supported by a 67.48% gross margin. Recent news highlights expansion of smoke-free products like ZYN and IQOS, now over 40% of revenue, driving growth amid industry shifts.
Outlook is positive with analyst consensus at Buy (68%) and a $212.17 price target, though elevated P/E of 26.46 and regulatory risks in tobacco remain concerns. Earnings growth and smoke-free product adoption are key catalysts, but investors should monitor debt levels and competitive pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →